Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226200 · ClinicalTrials.gov registry record · NA
Soluble CD23 Expression in Asthma Patients Treated With OMA
A NA study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT00226200 is a NA study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 80 participants.
The verdict
NCT00226200, a NA study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study involves a FDA approved drug, Omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. It works on IgE to control the allergic reaction. We are looking at the effects on non-allergic asthma. We hope to prove that Omalizumab will have the same effect on non-allergic asthmatics as it does allergic asthmatics.
Interventions
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00226200
The ClinicalTrials.gov registry entry for NCT00226200 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omalizumab is the first listed.
NCT00226200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00226200 about?
NCT00226200 is a clinical study titled "Soluble CD23 Expression in Asthma Patients Treated With OMA". This study involves a FDA approved drug, Omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. It works on IgE to control the allergic reaction. We are looking at the effects on non-allergic asthma. We hope to prove that Omalizumab w...
What is the current status of trial NCT00226200?
This trial is currently terminated. It is a NA study. The enrollment target is 80 participants. The study started on 2004-11. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00226200?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT00226200?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.